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THE mechanisms responsible for development of
inflammatory bowel disease (IBD) have not been
fully elucidated, although the main cause of disease
pathology is attributed to up-regulated inflammatory
processes. The aim of this study was to investigate
frequencies of polymorphisms in genes encoding
pro-inflammatory and anti-inflammatory markers in
IBD patients and controls. We determined genotypes
of patients with IBD (n /172) and healthy controls
(n /389) for polymorphisms in genes encoding
various cytokines (interleukin (IL)-1b, IL-6, tumour
necrosis factor (TNF), IL-10, IL-1 receptor antagonist).
Association of these genotypes to disease incidence
and pathophysiology was investigated. No strong
association was found with occurrence of IBD. Varia-
tion was observed between the ulcerative colitis study
group and the control population for the TNF-a 
/308
polymorphism (p /0.0135). There was also variation
in the frequency of IL-6 
/174 and TNF-a 
/308 geno-
types in the ulcerative colitis group compared with
the Crohn’s disease group (p /0.01). We concluded
that polymorphisms in inflammatory genes are asso-
ciated with variations in IBD phenotype and disease
susceptibility. Whether the polymorphisms are di-
rectly involved in regulating cytokine production,
and consequently pathophysiology of IBD, or serve
merely as markers in linkage disequilibrium with
susceptibility genes remains unclear.
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Introduction
Inflammatory bowel disease (IBD), a significant
health problem in the developed world, comprises
two chronic relapsing and remitting inflammatory
disorders of the gastrointestinal tract: ulcerative colitis
(UC) and Crohn’s disease (CD).
1 UC, which has a
slightly higher incidence than CD, affects only the
large bowel, whereas CD can affect any part of the
gastrointestinal tract. The general symptoms of UC
are malaise, lethargy, and anorexia accompanied by
diarrhoea with blood and mucus, abdominal discom-
fort, and fever.
1 The symptoms of CD tend to be more
varied, depending on its site in the digestive tract,
and can occur in a mild, moderate or severe form
characterised by cycles of remission and active
disease. These can include some or all of the
symptoms of UC, although extra-intestinal manifesta-
tions are also common in CD such as inflammation of
the eye, skin, joints, and mouth; arterial and venous
thrombosis; chronic hepatitis; and other complica-
tions involving the liver, biliary tract, and kidneys.
1 3
Little is known about the underlying immuno-
pathogenesis of IBD. However, both UC and CD
are characterised by activation of macrophages and T
lymphocytes; pro-inflammatory cytokine, chemo-
kine, and adhesion molecule expression; and an
inability to adequately down-regulate immune acti-
vation. IBD, particularly CD, is characterised by a
predominantly T helper (Th) 1 type profile, involving
the up-regulation of cytokines such as interleukin
(IL)-6, IL-8, IL-1b, and tumour necrosis factor (TNF)-
a.
4 6 TNF antibody therapy has been found to
improve both CD and UC, indicating a pivotal role
for this cytokine in these conditions.
7 9 Blocking IL-1
action with the IL-1 receptor antagonist (IL-1Ra) in
animals with immune-complex-mediated colitis re-
duces the severity of inflammation and lowers
eicosanoid concentrations in the bowel.
10,11 Reduced
levels of IL-10, an anti-inflammatory Th2 cytokine,
are also potentially important in the pathogenesis of
IBD, and encouraging results have been obtained
with IL-10 therapy in IBD when administered topi-
cally in UC and systemically in active CD patients.
12,13
A genetic background resulting in up-regulated
inflammation leading to IBD has been suggested by a
number of studies, including that of Tysk et al. who
estimated the heritability of CD (1.0, 95% confidence
interval, 0.34 /1.0) and UC (0.53, 95% confidence
interval, 0.24 /1.0) using the concordance rate in twin
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14 Using ‘age specific incidence data’ to calcu-
late the age-corrected empiric risk estimates, the risk
of developing IBD has been determined to be 8.9%
for offspring if either parent suffers IBD, 8.8% for
siblings of a patient, and 3.5% for parents of an
afflicted child.
15
We postulated that small differences in cytokine
levels as a result of gene polymorphisms may have an
important effect on the inflammatory response and
thus influence the pathophysiology of IBD. Here, we
investigate frequencies of a range of polymorphisms
in genes encoding pro-inflammatory cytokines (IL-
1b, IL-6, TNF-a, and TNF-b) and anti-inflammatory
markers (IL-10, IL-1Ra) in a group of individuals with
IBD and a large control population. We also aimed to
compare genotype frequencies in UC and CD
patients, in order to highlight possible differences
between these two IBD disease groups. A number of
the polymorphisms studied have been previously
reported to have functional effects on the levels of
the protein that they encode and have also been
associated with various inflammatory and/or auto-
immune diseases (Table 1).
Materials and methods
Patients and controls
Ethylenediamine tetraacetic acid anti-coagulated
whole blood was collected from 389 healthy blood
donors (female, 42%; male, 58%; mean age, 37.1
years; age range, 18 /65 years) and 172 patients with
established IBD recruited from St James’s Hospital,
Dublin (female, 59%; male, 41%; mean age of disease
onset, 30.8 years; median age of disease onset, 29.5
years; range of disease onset, 4 /69 years). The
disease group consisted of 64 patients with CD
(female, 72%; male, 28%; mean age of disease onset,
30 years; median age of disease onset, 29 years; range
of disease onset, 4 /69 years) and 108 patients with
UC (female, 52%; males, 48%; mean age of disease
onset, 31.5 years; median age of disease onset,
30 years; range of disease onset, 12 /61 years). Donor
bloods for use as control samples were collected
from The Northern Ireland Blood Transfusion Service
(n  /60) and The Blood Transfusion Service Board
(Dublin and Cork and mobile units throughout
the Republic of Ireland) (n  /329). The study
was approved by the St James’s Hospital ethics
committee and consent obtained from all participat-
ing subjects.
DNA isolation
DNA was extracted from whole blood using over-
night proteinase K (1 mg/ml) cell lysis at 378C in the
presence of 0.5% sodium dodecyl sulphate followed
by phenol/chloroform extraction and ethanol pre-
cipitation.
Table 1. Cytokine gene polymorphisms: effects on gene expression and disease associations
Gene Polymorphism Functional effect Disease association*
IL-6   /174 G0 /C
16 G:   / IL-6 in normal individuals and in reporter
gene assays (LPS/IL-1 stimulation)
16
S-JCA,
16 CAD
19
No association with IL-6 levels in CAD patients
17
or in sepsis patients
18
TNF-b   /252 A0 /G
(B20 /B1) (TNFB)
20
B2:   / TNF-a expression in stimulated PBMC,
21
in severe sepsis patients
22
Outcome in severe sepsis
22,24
No effect on TNF-a
20,23
B1:   / TNF-b in stimulated PBMC
20
B2:   / TNF-b in stimulated PBMC
23
No effect on TNF-b in stimulated PBMC
21
TNF-a   /308 G0 /AA :   / TNF-a expression in vitro
25 and in vivo
26 Outcome in meningococcal
disease,
28 septic shock
29 No effect on TNF-a response to LPS
27
IL-10   /592 C0 /A
30 Generally no association
A: ¡ / IL-10 expression in critically ill patients
31
Mortality in critically ill patients
31
IL-10   /1082 G0 /A
30 G:   / IL-10 expression in stimulated lymphocytes,
30
in control and CD patients
32
IBD
33
No effect on IL-10 levels
27
IL-1RN Intron 2, 86 bp VNTR
34 A2:   / IL-1Ra and ¡ / IL-1a expression in
GM-CSF-stimulated monocytes
35
IBD
38
A2: ¡ / IL-1Ra in cultured PBMC
36
A2:   / IL-1b in cultured PBMC
37
IL-1b   /3953 C0 /T
39 T:   / IL-1b expression in LPS-stimulated monocytes
39 IBD
42
No effect on in vivo IL-1b levels
40,41
  / or ¡ /, increase or decrease in expression compared with other alleles of the same polymorphism; 0 /, single base substitution; PBMC,
peripheral blood mononuclear cells; CAD, coronary artery disease; S-JCA, systemic-onset juvenile chronic arthritis; VNTR, variable number of
tandem repeats; LPS, lipopolysaccharide.
* Not all published disease associations are included in the table.
J. Balding et al.
182 Mediators of Inflammation Vol 13  2004Polymerase chain reaction, restriction enzyme
digestion, and agarose gel electrophoresis
Polymerase chain reaction (PCR) amplification of all
polymorphic sites was performed in a 50 ml total
volume. The standard reaction mix consisted of Taq
DNA Polymerase buffer with MgCl2 (Promega, Madi-
son, WI, USA) (50 mM KCl, 10 mM Tris /HCl (pH 9.0),
0.1% Triton X-100, and 1.5 mM MgCl2), 0.4 U of DNA
Taq polymerase, 2 ml of genomic DNA, 4% dimethyl
sulphoxide, 30 mM each of deoxyribonucleoside
triphosphates, and 0.2 mM each of sense primer and
antisense primer (Table 2). The cycling parameters
for each assay are presented in Table 3, along with
any changes to the standard PCR reaction mix.
Restriction enzymes (New England BioLabs, Beverly,
MA, USA; except Hsp 92 II, from Promega) used for
each assay are presented in Table 2. The IL-6, TNF-a,
IL-10 /1082, and IL-10 /592 PCR products were
digested with the appropriate enzyme overnight at
378C. The TNFB PCR product was digested for 3 h at
378C, and the IL-1b PCR product was digested for 12
ha t6 5 8C. Restriction digest products were run in the
appropriate percentage of agarose gel (Table 3)
containing 1.6 mg/ml of ethidium bromide.
Statistical analysis
Allele and genotype frequencies were compared
between patient and control groups, and between
patient subpopulations, by means of the chi-squared
test and Fischer’s exact test when appropriate. A chi-
squared pB /0.05 was considered statistically signifi-
cant. Allele frequencies were determined by gene
counting. Odds ratios and corresponding 95% con-
fidence intervals were estimated by cross-tabulation.
Statistics were performed using Statview software
(Statview version 4.5; Abacus Concepts Inc., Berke-
ley, CA, USA).
Results
IBD and controls
Genotype and allele frequencies for all seven poly-
morphisms in the control group, IBD group, UC
group, and CD group are presented in Table 4. No
association was found between any of the seven
polymorphisms in this study and the occurrence of
IBD, excepting the IL-1b polymorphism where the
CC genotype was at a higher frequency in the disease
population compared with the control population
(72% versus 61%, p  /0.046).
UC, CD and controls
The IBD study group can be divided into two groups:
patients suffering from UC and those suffering from
CD. A significant difference was observed when
comparing the UC study group with the control
population for the TNF-a /308 polymorphism, with
carriers of the   /308 A allele at a lower frequency in
the UC group (28%) compared with the control group
(40%) (p  /0.02). There was no association between
any of the other polymorphisms studied and the
occurrence of either form of IBD when comparing
with the control group, although the IL-1RN (gene
encoding the IL-1Ra protein) A2A2 genotype was
almost twice the frequency in the CD group (14%)
than that observed in either the control population
(8%) or the UC population (7%) (p  /0.088). Our
study found a significant difference in the frequency
of IL-6 /174 genotypes in the UC group (GG  /40%,
GC  /41%, CC  /19%) compared with the CD group
Table 2. PCR primer sequences with the position of the 5? base, restriction enzymes, and cut sites
Primer Sequence (5?  /3?) Position of
5? base
Restriction
enzyme
Restriction sites
Variant Constant
IL-6 /174 sense ATGACTTCAGCTTTACTCTT   /324 Hsp 92 II   /174   /296
IL-6 /174 antisense ATAAATCTTTGTTGGAGGGT   /81
TNFB sense* CCCTCCTGCACCTGCTGCCTGG   /112 Hinf I   /251   /196
TNFB antisense* AGAGGGG TGGATGCTTGGGTTC   /833
TNF-a /308 sense GGAGGCAATAGGTTTTGAGGGCCAT   /334 Nco I   /313   /162
TNF-a /308 antisense CTGTCTCGGT TTCTTCTCCATGGCG   /140
IL-10 /1082 sense TCTGAAGAAGTCCTGATGTC   /1248 Mnl I   /1085   /1196,   /1191
IL-10 /1082 antisense CTCTTACCTATCCCTACTTCC   /1059   /1081   /1174
IL-10 /592 sense GACTCCAGCCACAGAAGCTTA   /967 Rsa I   /594   /884,   /842,
IL-10 /592 antisense ATATCCTCAAAGTTCCCAAGC   /531   /834
IL-1b  /3953 sense GTGTTGTCATCAGACTTTGACCGTA   /3816 Taq I   /3952   /4052
IL-1b  /3953 antisense GAGAGCTTTCAGTTCATATCGACCA   /4073
IL-1RN sense** CTCAGCAACACTCCTAT Intron 2 N/A N/A N/A
IL-1RN antisense GCAGCAATAATGAAGAG Intron 2
* TNFB primers from Stu ¨ber et al.
22
** IL-1RN sense primer from Fang et al.
24
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similar association was seen for the TNF-a /308
polymorphism (UC group, GG  /72%, GA  /21%,
AA  /7%; CD group, GG  /53%, GA  /41%, AA  /
1%; p  /0.0135).
Age of IBD onset
No association was seen between age of disease
onset and any of the seven polymorphisms studied,
either for the IBD group as a whole or when dividing
into UC and CD groups.
Discussion
The pathophysiological mechanisms responsible for
the development of IBD have not yet been fully
determined. The main cause of disease pathology is,
as the name suggests, up-regulated inflammatory
processes, the consequence of which is inflammatory
cell infiltration in lamina propria, and crypt abscesses;
goblet cell depletion in the case of UC; and inflam-
mation in all bowel layers in CD, with lymphoid
hyperplasia and an increased presence of chronic
inflammatory cells.
1 Although infectious or other
external agents are probable contributors to IBD
pathogenesis, or might trigger disease onset, and the
immune system clearly mediates tissue damage in the
disease, it appears from available data that genetic
factors play a role in determining the susceptibility of
a given individual to IBD.
15 Since IBD is characterised
by a failure to confine the usual self-limited gut
inflammatory response, genes involved in determin-
ing the level of the immune response in the
inflammatory pathway might be risk factors in the
disease. We therefore examined the potential asso-
ciation of a group of polymorphisms in cytokine
Table 3. PCR cycling parameters, changes to standard reaction mix, and percentage agarose gel used in each assay
Polymorphism Cycles
(n)
Denaturation Annealing Elongation Changes to standard
reaction mix
Agarose
gel (%)
IL-6 /174 40 948C, 1 min 588C, 1 min 728C, 90 sec 3
TNFB* 37 958C, 30 sec 688C, 30 sec 748C, 42 sec 1 mM each primer 2
TNF-a /308 40 948C, 1 min 658C, 1 min 728C, 1 min 2
IL-10 /1082 40 948C, 1 min 588C, 1 min 728C, 1 min No DMSO 4
IL-10 /592 40 948C, 1 min 648C, 1 min 728C, 1 min 1 mM each primer 3
IL-1b  /3953 40 948C, 1 min 658C, 1 min 728C, 1 min 3
IL-1RN 86 bp VNTR 40 948C, 1 min 588C, 1 min 728C, 90 sec 1 mM each primer; 6% DMSO 2
DMSO, dimethyl sulphoxide; VNTR, variable number of tandem repeats.
* TNFB cycling parameters from Stu ¨ber et al.
22
Table 4. Genotype counts (%) and allele frequencies of seven polymorphisms in a control population and an IBD patient
population, and in subdivisions of the IBD population (UC and CD groups)
Polymorphism Genotype count (%) Allele frequency
Genotype Control (n  /389) IBD (n  /172) UC (n  /108) CD (n  /64) Allele Control IBD UC CD
IL-6 /174 GG 123 (32) 57 (33) 43 (40) 14 (22) G 0.57 0.58 0.61 0.54
GC 198 (51) 85 (49) 44 (41) 41 (64) C 0.43 0.42 0.39 0.46
CC 68 (17) 30 (18) 21 (19) 9 (14)
TNFB B1B1 52 (13) 25 (15) 18 (17) 7 (11) B1 0.40 0.39 0.38 0.41
B1B2 205 (53) 86 (50) 47 (43) 39 (61) B2 0.60 0.61 0.62 0.59
B2B2 132 (34) 61 (35) 43 (40) 18 (28)
TNF-a /308 GG 233 (60) 115 (67) 78 (72) 37 (58) G 0.78 0.81 0.83 0.78
GA 140 (36) 49 (28) 23 (21) 26 (41) A 0.22 0.19 0.17 0.22
AA 16 (4) 8 (5) 7 (7) 1 (1)
IL-10 /1082 GG 123 (32) 61 (36) 37 (34) 24 (38) G 0.55 0.58 0.56 0.60
GA 180 (46) 77 (44) 48 (45) 29 (45) A 0.45 0.42 0.44 0.40
AA 86 (22) 34 (20) 23 (21) 11 (17)
IL-10 /592 CC 235 (60) 116 (68) 72 (67) 44 (69) C 0.78 0.82 0.81 0.84
CA 139 (36) 50 (29) 31 (29) 19 (30) A 0.22 0.18 0.19 0.16
AA 15 (4) 6 (3) 5 (4) 1 (1)
IL-1b  /3953 CC 240 (62) 124 (72) 78 (72) 46 (72) C 0.78 0.83 0.83 0.83
CT 125 (32) 38 (22) 24 (22) 14 (22) T 0.22 0.17 0.17 0.17
TT 24 (6) 10 (6) 6 (6) 4 (6)
IL-1RN VNTR A1A1 183 (47) 73 (43) 48 (44) 25 (39) A1 0.69 0.66 0.685 0.617
A1A2 159 (41) 70 (41) 44 (41) 26 (41) A2 0.29 0.30 0.278 0.359
A1A4 0 (0) 1 (0.5) 1 (1) 0 (0) A3 0.02 0.03 0.028 0.024
A2A2 31 (8) 18 (10) 8 (7) 10 (15) A4 0.00 0.003 0.005
A1A3 15 (4) 9 (5) 6 (6) 3 (5) A5 0.00 0.003 0.005
A1A5 0 (0) 1 (0.5) 1 (1) 0 (0)
A2A3 1 (0.2) 0 (0) 0 (0) 0 (0)
VNTR, variable number of tandem repeats.
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patient subsets.
When comparing the complete IBD population
with controls, a significant variation in genotype
frequency of the IL-1b promoter polymorphism was
found. Higher levels of the pro-inflammatory cyto-
kine IL-1b would be expected to increase the like-
lihood of developing IBD, since higher levels of such
cytokines occur in this disease. This study detected
higher levels of IL-1b CC in IBD patients, a genotype
thought to be associated with low IL-1b levels.
39 It is
possible that the balance of high or low levels of IL-
1b is important in determining whether disease
develops or in determining disease phenotype, rather
than an overly pro-inflammatory genotype profile. It
must also be noted that the association seen in this
study was merely on the threshold of statistical
significance (p  /0.046) and thus needs further in-
vestigation in order to determine a real association
with the disease.
In the study population, there was a significant
variation in TNF-a /308 polymorphism genotype
frequency when comparing the control group with
the UC group. The control group contained a greater
frequency of heterozygotes, and the UC group a
greater frequency of homozygotes, especially GG,
and thus the UC group had a lower frequency of
carriers of the TNF-a /308 A allele. Previously, Vatay
et al. found the TNF-a /308 A allele to be less
frequent in both UC and CD patients compared
with controls,
43 and Bouma et al. found a lower
frequency of the TNF-a /308 A allele in UC patients
compared with healthy controls.
44 However, Louis et
al. found a modest non-statistically significant reduc-
tion of   /308 A allele frequency in CD patients
compared with both UC patients and controls.
45
Another study found no difference in TNF-a /308
allele frequencies between controls and patients with
fistulising CD, but did not look at frequency in UC
patients.
46 It therefore appears that there may be a
slight association between the occurrence of UC and
non-carriage of the   /308 A allele. This allele is
generally associated with increased serum TNF-a
levels, and the significance of its non-association
with UC, an inflammatory condition, is yet to be
elucidated, although it is possible that this poly-
morphism might play a role in the differences seen
between subsets of patients with UC and CD.
When comparing the two IBD disease groups, it
was observed that there was a higher number of IL-
6 /174 and TNF-a /308 heterozygotes in the CD
group compared with the UC group for both poly-
morphisms. TNFB genotypes also differed between
UC and CD groups, but did not reach statistical
significance; this difference was possibly caused by
linkage of the TNFB polymorphism to the TNF-a /308
polymorphism. The explanation for why certain
patient groups should contain a higher number of
heterozygotes or homozygotes is unclear. Rather than
being directly associated with the disease, these
genotypes may serve merely as genetic markers for
other genes. The associations between IBD and the
TNF-a polymorphism have already been discussed.
The IL-6 /174 polymorphism was previously investi-
gated in 169 CD patients, 133 UC patients and 440
healthy controls, and no significant difference in
allele, genotype, or carrier frequencies between
patients and controls was observed.
47 The signifi-
cance of the differences of the TNF-a and IL-6
polymorphisms between the UC and CD groups
seen in our study is not clear, but points to a potential
difference in the pathophysiology of these two
diseases, and the possibility that the effect of higher
or lower levels of TNF-a and IL-6 may play different
roles in patients with UC and CD.
The IL-10 /1082 polymorphism has been asso-
ciated with susceptibility to IBD (UC or CD), and
more significantly to UC alone;
33 however, our study
found no evidence to support these results, concur-
ring with the results of Klein et al. who looked at
both   /1082 and   /592 polymorphisms in 142 CD
patients, 104 UC patients and 400 controls, and found
no differences in allele frequencies of either poly-
morphism between the groups studied.
48 Allele 2 of
the IL-1RN gene has been found at a greater
frequency in a UC population compared with a
control group.
38 It is interesting to note that, although
not statistically significant, the IL-1RN A2A2 genotype
in our study was double the frequency in the CD
group compared with both the UC and control
groups, although this differs to the previous study
where the association was for UC not CD. However, a
previous study looked at the IL-1RN genotype in a
large IBD population (n  /529) (divided into IBD
subgroups) compared with controls (n  /289) and
found no differences in genotype or allele frequen-
cies, looking in particular at IL-1RN allele 2,
49 and it
therefore appears likely that no real association
between IBD and the IL-1RN VNTR exists. This lack
of association has also been confirmed by a further
study.
50
In conclusion, this study provides evidence that
polymorphisms in genes involved in the inflamma-
tory response participate in determining susceptibil-
ity and disease phenotype in IBD patients, although
not to a highly significant degree. Whether the
polymorphisms are directly involved in regulating
cytokine production, and consequently disease
pathophysiology of IBD, or serve merely as markers
that are in linkage disequilibrium with susceptibility
genes is unclear. There does not appear to be any
clear-cut correlation between alleles or genotypes
that are associated with higher pro-inflammatory
cytokine levels and disease occurrence. However, it
may be that an imbalance in levels of the cytokines is
Cytokine gene polymorphisms in IBD
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than an overall pro-inflammatory profile.
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